Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir

IF 2.1 4区医学 Q3 VIROLOGY

Future Virology Pub Date : 2024-02-26 DOI:10.2217/fvl-2023-0132

Roberta Monardo, A. Mastrangelo, Laura Galli, A. Tomelleri, V. Spagnuolo, C. Oltolini, Giacomo Ponta, C. Campochiaro, G. Cavalli, L. Dagna, F. Ciceri, Paola Cinque, P. Scarpellini, Antonella Castagna, M. Ripa

引用次数: 0

Abstract

Aim: Aim of this study was to evaluate the effect of anakinra (ANK) addition to remdesivir (RDV) on all-cause 28-day mortality in patients hospitalized with COVID-19. Patients & methods: ANK was administered intravenously at a dose of 5 mg/kg every 12 h in patients with severe respiratory failure and pronounced inflammatory status. 58 patients were treated with RDV + ANK, 219 patients with RDV. Results: The estimate of mortality at 28 days was 17.2% in the RDV + ANK group and 21.4% in the RDV group. Median time to death was 14 days in the RDV + ANK group and 19 in the RDV group. Conclusion: Despite severe respiratory failure and pronounced inflammatory status, patients who received RDV + ANK had similar mortality compared with patients who received RDV.

查看原文本刊更多论文

在接受雷米替韦治疗的 COVID-19 患者中实际使用大剂量阿纳金雷

目的：本研究旨在评估在雷米地韦（RDV）基础上加用阿纳金拉（ANK）对COVID-19住院患者28天内全因死亡率的影响。患者与方法对患有严重呼吸衰竭和明显炎症的患者静脉注射ANK，剂量为每12小时5毫克/千克。58 名患者接受了 RDV + ANK 治疗，219 名患者接受了 RDV 治疗。治疗结果RDV+ANK组在28天内的估计死亡率为17.2%，RDV组为21.4%。RDV + ANK 组的中位死亡时间为 14 天，RDV 组为 19 天。结论尽管存在严重的呼吸衰竭和明显的炎症状态，但接受 RDV + ANK 治疗的患者的死亡率与接受 RDV 治疗的患者相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Virology 医学-病毒学

CiteScore

4.00

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.